Neurotech Receives Priority Review of Biologics License Application for NT-501 as a Treatment for Macular Telangiectasia Type 2
June 20, 2024
LMRI would like to share the news that Neurotech has received Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a treatment for MacTel. For more information, please refer to the Neurotech press release. For questions about NT-501, we encourage you to refer to the Patients section of the Neurotech website.